Skip to content
Screener

Capricor Therapeutics CAPR Q2 2025 earnings

Reported August 11, 2025 · After market close

Revenue-
EPS-$0.57Miss by $0.09
EPS estimate-$0.48

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$41.7M
EPS estimate-$0.14

Financials

Q2 2025

Income statement

See full
Revenue--100%
Operating income-$27.7M-139%
Net income-$25.9M-136%
EPS (diluted)-$0.57-62.9%

Balance sheet

See full
Cash & equivalents$23.2M+117%
Total debt$1.0M-80.0%
Total equity$105.0M+813%
Total assets$133.6M+249%

Cash flow

See full
Operating cash flow-$20.1M-63.7%
CapEx$287.7K+377%
Free cash flow-$20.4M-65.3%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$422.8M+177%
Enterprise value$400.6M+172%
P/S31.6×+26.0×

Profitability

See full
Operating margin-548.1%-733pp
Net margin-522.5%-692pp
FCF margin-408.3%-770pp

Returns & leverage

See full
Return on equity-120.2%-49.2pp
Debt / equity0×-0.4×
Current ratio4.4×+3.0×

FAQ

When did Capricor Therapeutics report Q2 2025 earnings?
Capricor Therapeutics (CAPR) reported Q2 2025 earnings on August 11, 2025 after market close.
What were Capricor Therapeutics's Q2 2025 revenue and EPS?
Capricor Therapeutics reported revenue of - and eps of $-0.57 for Q2 2025.
Did Capricor Therapeutics beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.48 by $0.09.
How did Capricor Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $4.0M a year earlier and eps declined 62.9% from $-0.35.
Where can I find Capricor Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001558370-25-011047) and the 10-Q periodic report (0001558370-25-011084) directly on SEC EDGAR. The filing index links above go to sec.gov.